Antiviral Drugs for Lassa Fever Virus

拉沙热病毒的抗病毒药物

• 批准号: 7282546
• 负责人: SEAN M AMBERG
• 金额: $ 116.08万
• 依托单位: SIGA TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7282546
• 关键词: Africa; Animal Model; Animal Viruses; Animals; Antiviral Agents; Arenavirus; Award; Back; Biological; Biological Assay; Biology; Categories; Cavia; Cells; Centers for Disease Control and Prevention (U.S.); Characteristics; Chemical Structure; Chemicals; Chemistry; Clinical; Condition; Cultured Cells; Data; Developed Countries; Developing Countries; Development; Disease; Dose; Drug Compounding; Drug Exposure; Drug Formulations; Drug Kinetics; Drug or chemical Tissue Distribution; Drug resistance; Escape Mutant; Evaluation; Excretory function; Exhibits; Funding; Genetic; Glycoproteins; Goals; Grant; Health; Human; In Vitro; Individual; Investigational Drugs; Investigational New Drug Application; Lassa Fever; Lassa fever virus; Lassa virus; Lead; Maps; Membrane Glycoproteins; Metabolic; Metabolism; Modeling; Molecular Genetics; Monitor; National Institute of Allergy and Infectious Disease; Numbers; Oral; Oral Administration; Organ; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phase; Predisposition; Process; Program Development; Property; Public Health; Purpose; Qualifying; Range; Research Personnel; Resistance; Retroviridae; Risk; Safety; Series; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Structure; Structure-Activity Relationship; Tacaribe Complex Viruses; Techniques; Technology; Testing; Toxic effect; Toxicology; United States Food and Drug Administration; United States National Institutes of Health; Variant; Viral; Virulence; Virus; Virus Diseases; Virus Replication; Work; absorption; analog; analytical method; base; biodefense; biosafety level 4 facility; chemical synthesis; cytotoxic; design; desire; drug development; drug metabolism; drug resistant virus; efficacy evaluation; env Gene Products; fitness; hemorrhagic fever virus; in vivo; inhibitor/antagonist; mutant; nonhuman primate; pathogen; pre-clinical; prevent; programs; prospective; research study; scaffold; small molecule libraries; trait

DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the world. The CDC and NIAID have identified Lassa fever virus as a Category A priority pathogen, indicating the highest degree of threat to public health. The purpose of our biodefense program is to develop safe and effective drugs for preventing and treating diseases caused by Category A viruses. To that end, a large and diverse library of small molecule compounds was screened to identify inhibitors that target the essential Lassa surface glycoprotein and thus block viral entry into the host cell. A number of these potent antiviral compounds and their related analogs have exhibited informative chemical structure-biological activity relationships (SAR). The goal of the Phase II proposal is to advance these compounds toward clinical development, to submit an application for an Investigational New Drug (IND) for the strongest candidate, and to identify at least one additional preclinical candidate as a potential back-up compound if needed. Lead compounds will be optimized by criteria of potency, toxicity, metabolism, and pharmacokinetics. Compounds that demonstrate acceptable traits will be evaluated for efficacy in animal models of Lassa fever. These experiments will be performed initially in guinea pigs, with efficacious compounds further tested in nonhuman primates. In addition, the mechanism of antiviral action will be explored both directly and by examination of prospective viral escape mutants. Replication-deficient retroviruses that incorporate a heterologous envelope protein such as the Lassa fever virus glycoprotein (viral pseudotypes) will be used to assess compound potency and mechanism of action; these experiments can be performed using biosafety level 2 (BSL-2) conditions. Results will be validated in BSL-4 facilities using authentic Lassa fever virus; animal studies using Lassa fever virus will also be conducted in BSL-4 facilities.

描述（由申请人提供）：出血热病毒是严重的全球健康问题，也是潜在的生物武器。特别是拉沙热病毒每年在西非感染数十万人，有意或无意地将这种病原体输出到该区域以外，对世界发达国家构成严重风险。美国疾病控制与预防中心和NIAID已将拉沙热病毒确定为a类优先病原体，表明对公共卫生的威胁程度最高。我们的生物防御计划的目的是开发安全有效的药物来预防和治疗由A类病毒引起的疾病。为此，筛选了一个大而多样的小分子化合物文库，以确定针对必需的拉沙表面糖蛋白的抑制剂，从而阻止病毒进入宿主细胞。这些有效的抗病毒化合物及其相关类似物已经显示出丰富的化学结构-生物活性关系（SAR）。II期申请的目标是推进这些化合物的临床开发，为最强的候选药物提交研究新药（IND）申请，并在需要时确定至少一种额外的临床前候选药物作为潜在的备用化合物。先导化合物将通过效价、毒性、代谢和药代动力学标准进行优化。将对表现出可接受特性的化合物在拉沙热动物模型中的疗效进行评估。这些实验将首先在豚鼠身上进行，并在非人类灵长类动物身上进一步测试有效化合物。此外，抗病毒作用的机制将通过直接和检查潜在的病毒逃逸突变体来探索。结合异源包膜蛋白（如拉沙热病毒糖蛋白）的复制缺陷逆转录病毒（病毒伪型）将用于评估复合效力和作用机制；这些实验可以在生物安全等级2 （BSL-2）条件下进行。结果将在BSL-4设施中使用真实的拉沙热病毒进行验证；使用拉沙热病毒的动物研究也将在BSL-4设施中进行。